Alvotech is a global biopharmaceutical company dedicated to become one of the leaders in the biosimilar monoclonal antibody market. Alvotech is an independent sister company of the international pharmaceuticals company Alvogen. The company is headquartered in Reykjavik, Iceland, and has an increasingly global presence and a broad network of partners around the world.
Alvotech has six key biosimilar molecules in development and a new state-of-the-art manufacturing plant for development and commercial supply. Alvotech is investing over $500 million in the development of its pipeline and facility.